# Mindfulness and Biofeedback for Anxiety Disorders

> **NCT07628153** · PHASE4 · COMPLETED · sponsor: **I.M. Sechenov First Moscow State Medical University** · enrollment: 188 (actual)

## Conditions studied

- Anxiety Disorders

## Interventions

- **DEVICE:** "Reacor" adaptive biofeedback system
- **DRUG:** Escitalopram 10 mg/day
- **COMBINATION_PRODUCT:** Biofeedback plus Escitalopram

## Key facts

- **NCT ID:** NCT07628153
- **Lead sponsor:** I.M. Sechenov First Moscow State Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-11
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628153, "Mindfulness and Biofeedback for Anxiety Disorders". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07628153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*